Christian S. Schade - 25 Feb 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Chairman & CEO, Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
25 Feb 2022
Net transactions value
-$37,661
Form type
4
Filing time
01 Mar 2022, 16:02:52 UTC
Previous filing
17 May 2021
Next filing
14 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Tax liability $37,661 -21,644 -12% $1.74 155,016 25 Feb 2022 Direct F1
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 1,000 25 Feb 2022 By adult child F2
holding APRE Common Stock 5,000 25 Feb 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 55,166 restricted stock units.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.